554 Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a BCMAxCD38xCD3 trispecific antibody, in TRIgnite-1, the first-in-human (FIH) phase 1 study in relapsed/refractory multiple myeloma (RRMM) — Andrew Garton (2025) | RDL Network
554 Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a BCMAxCD38xCD3 trispecific antibody, in TRIgnite-1, the first-in-human (FIH) phase 1 study in relapsed/refractory multiple myeloma (RRMM)
Hang Quach, Bradley Augustson, David Levitz, Hanlon Sia, Eben I. Lichtman, Nicole Wong Doo, Michaela Liedtke, Camille Martinet, Vinu Menon, Andrew Garton, Cyril Konto, Lida Pacaud, Beata Holkova, Amit Khot
Eben I. Lichtman, Amit Khot, Bradley Augustson, David Levitz, Hanlon Sia, Nicole Wong Doo, Michaela Liedtke, Camille Martinet, Vinu Menon, Andrew Garton, Harjeet Sembhi, Maria Pihlgren, Cyril Konto, Beata Holkova, Lida Pacaud, Hang Quach
Shaji Kumar, Magdalini Migkou, Manisha Bhutani, Andrew Spencer, Sikander Ailawadhi, Anna Kalff, Farzana L. Walcott, Nabendu Pore, D. Gibson, Fujun Wang, Lily Cheng, Ioannis Kagiampakis, Marna Williams, Krista Kinneer, Yu Jiang, Jeffrey A. Zonder, Jeremy T. Larsen, Shreerang Sirdesai, Andrew J. Yee, Meletios A Dimopoulos
Meletios A Dimopoulos, Magdalini Migkou, Manisha Bhutani, Sikander Ailawadhi, Anna Kalff, Farzana L. Walcott, Nabendu Pore, Miranda Brown, Fujun Wang, Lily Cheng, Ioannis Kagiampakis, Marna Williams, Krista Kinneer, Yuling Wu, Yu Jiang, Robert Kubiak, Jeffrey A. Zonder, Jeremy T. Larsen, Shreerang Sirdesai, Andrew J. Yee, Shaji Kumar
Discussion(0)
No comments yet. Be the first to comment.